Effectively Shape Your Drug Development and Launch Strategy
GeneScape is specialized in epidemiology for rare, ultra-rare, and orphan diseases. We will bring you further than the basic prevalence or incidence indications
(e.g. 1 in 100,000 births).
Our expertly curated data evaluation and integrated genomic analysis pipeline allow us to leverage increasingly larger datasets to help you transform your drug development and launch strategies.
Your Target
Patient Population
GeneScape understands that the mode of action for innovative therapies shapes the target patient profile.
Whether you are targeting a pathway, a gene, or even a specific mutation, we can develop the models that are appropriate for your therapy to quantify the addressable patient population.
Epidemiology & Demographics
Not only can we help identify and quantify the scale of unmet need for target populations; we also support models for key characteristics of target patients and where best to find them.
Population Genetics Modeling
By leveraging GeneScape's
integrated genome analysis pipeline we can estimate patient numbers for many indications, independent of diagnosis.
Bio-Curation
The amount of
genetic data can be overwhelming but don't lose out on key insights. Whether you are a researcher, clinician, or a company, we offer tailored insights and solutions.
GeneScape in Brief
7
Pharma/Biotech & Rare Disease Research Partners
780K+
Integrated Human Genomes
20+
Populations Modeled for
Innovative Targets
Impact of Applying GeneScape to Your Programs
Identify New Targets
Comprehensive review of potential targets suited to your technology
Reliable Patient Estimates
Improved accuracy in market forecasts and program valuation
Uncover Patient Subsets
Uncover undiagnosed or poorly diagnosed patient subsets
Competitive Landscape
Identify potential overlap within your own portfolio or a competitor's portfolio
Patient Demographics
Provide population
characteristics to support regulatory submission and
trial design
Focused Strategy
Clearly define addressable patient segments to provide realistic recruiting and market expectations
Current & Previous Collaborators
